1100598-48-8 Usage
General Description
BenzeneMethanol, 3-[5-[(1-Methyl-4-piperidinyl)Methoxy]-2-pyriMidinyl]- is a chemical compound with a complex molecular structure that includes benzene, methanol, and pyrimidine. It is also known by the trade name TAK-632 and is used in scientific research as a potential inhibitor of cancer cell growth. BenzeneMethanol, 3-[5-[(1-Methyl-4-piperidinyl)Methoxy]-2-pyriMidinyl]- has attracted interest as a potential anti-cancer drug due to its ability to target specific cellular pathways involved in cancer progression. It has also been studied for its potential application in the treatment of other diseases such as Alzheimer's and Parkinson's. However, further research is needed to fully understand its potential therapeutic benefits and side effects.
Check Digit Verification of cas no
The CAS Registry Mumber 1100598-48-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,0,0,5,9 and 8 respectively; the second part has 2 digits, 4 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1100598-48:
(9*1)+(8*1)+(7*0)+(6*0)+(5*5)+(4*9)+(3*8)+(2*4)+(1*8)=118
118 % 10 = 8
So 1100598-48-8 is a valid CAS Registry Number.
1100598-48-8Relevant articles and documents
NOVEL POLYMORPHIC FORMS OF 3-(1-{3-[5-(1-METHYL-PIPERIDIN-4YLMETHOXY)-PYRIMIDIN-2-YL]-BENZYL}-6-OXO-1,6-DIHYDRO-PYRIDAZIN-3-YL)-BENZONITRILE HYDROCHLORIDE SALT AND PROCESSES OF MANUFACTURING THEREOF
-
Page/Page column 15, (2010/08/04)
The present invention relates to hydrochloride solvates of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile and crystalline modifications thereof. The present invention further relates to processes of manufacturing these crystalline modifications as well as their use in the treatment and/or prophylaxis of physiological and/or pathophysiological conditions, which are caused, mediated and/or propagated by the inhibition, regulation and/or modulation of signal transduction of kinases, in particular by the inhibition of tyrosine kinases, e.g. pathophysiological conditions such as cancer.